Monoclonal Antibody Therapy With Sargramostim and Interleukin-2 in Treating Children With Neuroblastoma

Inclusion Criteria:

* Must have recently completed a course of myeloablative therapy followed by autologous stem cell (bone marrow or peripheral blood) rescue (ASCT)
* Patients must have a diagnosis of neuroblastoma based upon tumor histology or bone marrow metastases and elevated urine catecholamine metabolites; greater than 98% of neuroblastomas are GD2-positive without intratumor heterogeneity, so these tumors will not be immunostained prior to study entry
* Patients entered on CCG-3951 may become eligible following the third course of high-dose chemotherapy followed by peripheral blood stem cell (PBSC) rescue; patients treated on institutional (local) protocols of high-dose chemotherapy with PBSC rescue may also become eligible after one or more courses of PBSC rescue
* Patients must enter onto study within 8 weeks after the total absolute phagocyte count \[neutrophils (segs + bands) + monocytes\] is \> 1,000/uL; the APC criteria include counts obtained while on G-CSF therapy
* Patients must have a performance status of 0, 1 or 2 and patients must have a life expectancy of \>= 2 months
* Serum creatinine =\< 1.5 x normal, or creatinine clearance or radioisotope glomerular filtration rate (GFR) \>= 60 ml/min/1.73 m\^2
* Total bilirubin =\< 1.5 x normal
* Serum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase \[AST\]) or serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase \[ALT\]) =\< 5 x normal
* Veno-occlusive disease, if present, should be stable or improving
* Shortening fraction of \>= 27% by echocardiogram, or ejection fraction of \> 50% by gated radionuclide study
* Forced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC) \> 60% of predicted by pulmonary function test
* For children who are unable to do pulmonary function tests (PFTs), no evidence of dyspnea at rest, no exercise intolerance, and a pulse oximetry \> 94% on room air
* Patients with seizure disorder may be enrolled if on anticonvulsants and well controlled
* Central nervous system (CNS) toxicity \< grade 2
* Patients must have a double lumen catheter or single lumen and peripheral IV so that interleukin (IL)-2 and ch14.18 can be given separately
* Patients who remain evaluable for response on Phase II/III studies (i.e. CCG-3891) are not eligible for this study; however, patients treated on Phase I studies (i.e. CCG-3951) and patients who are no longer evaluable on Phase II/III studies (i.e. progressive disease following therapy) will be eligible
* Patients who were previously treated with antibody 14.G2a or ch14.18 are ineligible for this study
* Patients requiring chronic use of corticosteroids are ineligible
* Corticosteroid, immunosuppressive drugs, myelosuppressive chemotherapy, and retinoic acid must not be given within 14 days prior to study entry
* Radiation therapy must not be given within seven days prior to study entry or during therapy
* All patients and/or their parents or legal guardians must sign a written informed consent
* All institutional, FDA, and NCI requirements for human studies must be met